729 related articles for article (PubMed ID: 31276706)
1. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis.
Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J
Clin Cancer Res; 2011 Feb; 17(3):416-26. PubMed ID: 21159888
[TBL] [Abstract][Full Text] [Related]
3. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract][Full Text] [Related]
4. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.
Wadayama B; Toguchida J; Yamaguchi T; Sasaki MS; Yamamuro T
Br J Cancer; 1993 Dec; 68(6):1134-9. PubMed ID: 8260365
[TBL] [Abstract][Full Text] [Related]
5. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
[TBL] [Abstract][Full Text] [Related]
6. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
Pérot G; Chibon F; Montero A; Lagarde P; de Thé H; Terrier P; Guillou L; Ranchère D; Coindre JM; Aurias A
Am J Pathol; 2010 Oct; 177(4):2080-90. PubMed ID: 20884963
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
8. Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.
Guijarro MV; Dahiya S; Danielson LS; Segura MF; Vales-Lara FM; Menendez S; Popiolek D; Mittal K; Wei JJ; Zavadil J; Cordon-Cardo C; Pandolfi PP; Hernando E
Am J Pathol; 2013 Jun; 182(6):2015-27. PubMed ID: 23708211
[TBL] [Abstract][Full Text] [Related]
9. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas.
Toguchida J; Yamaguchi T; Ritchie B; Beauchamp RL; Dayton SH; Herrera GE; Yamamuro T; Kotoura Y; Sasaki MS; Little JB
Cancer Res; 1992 Nov; 52(22):6194-9. PubMed ID: 1423262
[TBL] [Abstract][Full Text] [Related]
10. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
11. [Cytogenetic data on sarcomas of the bone and soft tissue].
Aurias A
Bull Cancer; 1988; 75(5):423-9. PubMed ID: 3165034
[TBL] [Abstract][Full Text] [Related]
12. p53: functions, mutations and sarcomas.
Hung J; Anderson R
Acta Orthop Scand Suppl; 1997 Feb; 273():68-73. PubMed ID: 9057590
[TBL] [Abstract][Full Text] [Related]
13. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.
Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL
Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948
[TBL] [Abstract][Full Text] [Related]
16. p53 immunohistochemical analysis of fusion-positive uterine sarcomas.
Mohammad N; Stewart CJR; Chiang S; Turashvili G; Dickson BC; Ng TL; Köbel M; McCluggage WG; Croce S; Lee CH
Histopathology; 2021 May; 78(6):805-813. PubMed ID: 33118176
[TBL] [Abstract][Full Text] [Related]
17. p53 gene mutations and p53 protein expression in human soft tissue sarcomas.
Yoo J; Lee HK; Kang CS; Park WS; Lee JY; Shim SI
Arch Pathol Lab Med; 1997 Apr; 121(4):395-9. PubMed ID: 9140310
[TBL] [Abstract][Full Text] [Related]
18. Current molecular and therapeutic advances in liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, and angiosarcoma.
Tanriverdi O; Yildiz A
J Oncol Pharm Pract; 2022 Apr; 28(3):635-645. PubMed ID: 35043739
[TBL] [Abstract][Full Text] [Related]
19. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas.
Wunder JS; Czitrom AA; Kandel R; Andrulis IL
J Natl Cancer Inst; 1991 Feb; 83(3):194-200. PubMed ID: 1988704
[TBL] [Abstract][Full Text] [Related]
20. [Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region].
Ducimetière F; Lurkin A; Ranchère-Vince D; Decouvelaere AV; Isaac S; Claret-Tournier C; Suignard Y; Salameire D; Cellier D; Alberti L; Bringuier PP; Blay JY; Ray-Coquard I
Bull Cancer; 2010 Jun; 97(6):629-41. PubMed ID: 20504759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
